- cafead   Mar 05, 2024 at 11:22: AM
via UK-based pharmaceutical company ViiV Healthcare has reported data from a Phase I trial of its investigational formulation, cabotegravir ultra long-acting (CAB-ULA), for HIV treatment and prevention.
article source
article source